• Laura R Pfrommer, Melissa Schoeps, Maria Blettner, Daniel Wollschläger, Nils Herm-Stapelberg, Lukas Mittnacht, Philipp Kachel, Klaus Jahn, von LoewenichFriederike DFD, and GianicoloEmilio A LEAL.
• Institute for Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University Mainz; Division of Vaccine Documentation, Cancer Registry Rhineland-Palatinate, Mainz; Rhineland-Palatinate Ministry of Science and Health, Mainz; Institute for Virology, University Medical Center of the Johannes Gutenberg University Mainz; Institute of Clinical Physiology of the Italian National Research Council (IFCCNR), Lecce, Italy.
• Dtsch Arztebl Int. 2022 Oct 28; 119 (43): 727734727-734.

BackgroundIn Rhineland-Palatinate, most COVID-19 vaccinations are centrally registered by the Rhineland-Palatinate Division of Vaccine Documentation, which includes self-reported vaccination reactions (SRVR) and their level of perceived intensity. We analyzed the occurrence of SRVR reported between 12/2020 and 12/2021 in relation to the different vaccination regimens involving BioNTech/Pfizer (BNT) and Moderna (m1273) mRNA vaccines and AstraZeneca (ChAd) and Johnson & Johnson (Ad26) viral vector vaccines.MethodsUsing sex-specific logistic regression models, we analyzed the occurrence of all local and systemic SRVR, as well as the occurrence of local and systemic SRVR that were self-rated as "severe" by the vaccinated persons, in relation to the vaccine of the first vaccination and the vaccination regimen of the second vaccination (BNT/BNT, ChAd/ChAd, m1273/m1273, ChAd/ BNT, ChAd/m1273). Vaccination with BNT or the BNT/BNT regimen formed the reference category for the estimated odds ratios (OR) with respective 95% confidence intervals.ResultsOf all those vaccinated, 40.7% provided valid information on SRVR after the first vaccination and 33.8% after the second vaccination. As a result, 887 052 individuals were included in the analyses. Their median age was 60 years, and 58% were women. The most common vaccination regimen was BNT/BNT (67.3%). The most common SRVR were pain at the injection site and fatigue. Self-reported reactogenicity after the first vaccination was lowest for BNT. Self-reported systemic reactogenicity was notably higher after vaccination with a vector vaccine. After the second vaccination, self-reported reactogenicity was lowest after a ChAd/ChAd regimen and highest after an m1273 second vaccination.ConclusionWith overall acceptable tolerability, differences in self-reported reactogenicity were evident depending on the particular COVID-19 vaccines and vaccination regimens in question.

16 keywords...

hide…